Skip to main content
OpenTrials
Completed

NCT Number: NCT03150498

A Food Effects Study and Optional Multi Dose Study to Assess PK of BTD-001

This is a single-centre, open-label study in healthy male and non-pregnant, non-lactating females. The study will consist of up to 2 parts; the decision to proceed to the optional second part will be made following review of Part 1 data.

Part 1 is a single dose, two period crossover to assess food affect of oral BTD-001.

Optional Part 2 is a non-randomised, single arm study multi dose design to evaluate PK profile of BTD-001

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Quotient Clinical

Ruddington, Nottingham, NG11 6JS, United Kingdom

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy adult males and non-pregnant, non-lactating females aged 18-55 years old
  • BMI between18.0-35.0 kg/m2 unless investigator deems not clinically significant
  • Provide written consent
  • Agrees to protocol specified contraception

Exclusion criteria

  • Received any investigational treatment within last 3 months
  • Subjects who are study site employees, or immediate family members of a study site or sponsor employee
  • Subjects who have previously been enrolled in this study
  • History of any drug or alcohol abuse in the past 2 years
  • Regular alcohol consumption in males >21 units per week
  • Current smokers and those who have smoked, including nicotine replacement or e-cigarates within the last 12 months.
  • Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator at screening
  • Clinically significant abnormal lab results
  • Positive drugs of abuse test result
  • Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results
  • Evidence of renal impairment at screening
  • History of or current seizure disorder or history of syncope, unexplained loss of consciousness or seizure in the past 3 years
  • Clinically significant medical/psychiatric history findings, or physical/neurological examination findings or significant history of or current suicidal ideation or behaviour
  • History of or current significant pulmonary, cardiac, renal, hepatic, chronic respiratory, gastrointestinal, neurological or psychiatric disease, substance dependence, porphyria, malignancy (with exception of local cutaneous squamous or basal cell carcinomas or local cervical squamous cell cancer resolved after resection) or hypothyroidism
  • Subjects with QT interval corrected for heart rate according to Fridericia's formula of >430 msec in males and >450 msec in females
  • Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients
  • Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hayfever is allowed unless it is active
  • Donation or loss of greater than 400 mL of blood within the previous 3 months Subjects who are taking, or have taken, any prescribed or over-the-counter drug (other than up to 4 g per day paracetamol,hormone replacement therapy and hormonal contraception) or herbal remedies
  • Failure to satisfy the investigator of fitness to participate for any other reason

Treatment and study plan

BTD-001

Drug

BTD-001 in fed vs fasted state

Primary outcomes

  1. Part 1 & Part 2 - Cmax of BTD-001 and major metabolites

    Time frame: [Maximum 30 days]

    Maximum Observed Plasma Concentration

  2. Part 1 & Part 2 - Tmax of BTD-001 and major metabolites

    Time frame: [Maximum 30 days]

    Time to Maximum Observed Plasma Concentration

  3. Part 1 & Part 2 - AUC(0-last): of BTD-001 and major metabolites

    Time frame: [Maximum 30 days]

    Area Under the Curve for Observed Plasma Concentration

  4. Part 1 & Part 2 - T1/2 of BTD-001 and major metabolites

    Time frame: [Maximum 30 days]

    elimination half-life

Secondary outcomes

  1. Physical Examination

    Time frame: [Maximum 30 days]

    Safety and tolerability of BTD-001 by assessing physical examination

  2. Vital Signs

    Time frame: [Maximum 30 days]

    Safety and tolerability of BTD-001 by assessing vital signs

  3. ECG

    Time frame: [Maximum 30 days]

    Safety and tolerability of BTD-001 by assessing ECG

  4. Adverse Events

    Time frame: [Maximum 30 days]

    Safety and tolerability of BTD-001 by assessing AEs

  5. Safety Lab Test

    Time frame: [Maximum 30 days]

    Safety and tolerability of BTD-001 by assessing safety lab tests

  6. Likert Scales

    Time frame: [Maximum 30 days]

    To assess BTD-001 withdrawal in healthy volunteers

Other outcomes

  1. Karolinska Sleepiness Scale

    Time frame: [Maximum 30 days]

    To assess sleepiness using the KSS

Sponsors and collaborators

Lead sponsor

Balance Therapeutics

Industry

Registry information

Official study title

A Phase 1 Cross-over Study to Determine Food Effects on the Pharmacokinetics of Oral BTD-001 and Metabolites in Healthy Volunteers, Followed by an Optional Multiple Dose Study to Assess Pharmacokinetics of Oral BTD-001

Important dates

Study start
2017
Primary completion
2017
Study completion
2017
First posted
May 12, 2017
Registry last updated
Oct 24, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.